Video

Girish Hiremath, MD, MPH: Pediatric Compliance to EoE Therapies

Author(s):

An expert discusses a study assessing the effects of low compliance to eosinophilic esophagitis therapies among pediatric patients.

Children with eosinophilic esophagitis (EoE) may face barriers or challenges when it comes to adhering to or properly using therapeutic agents like proton pump inhibitors (PPI) and topical corticosteroids (TCS).

Improper use of these pharmacologic agents can potentially lead to persistence of eosinophilic inflammation or esophageal remodeling and food impaction.

A new study presented at the annual American College of Gastroenterology (ACG) 2020 conference assessed the relationship between PPI/TCS compliance and EoE status and the peak eosinophil count (PEC) in pediatric patients. The study also sought to determine whether there were any patient factors that were associated with 100% compliance.

The team, led by Girish Hiremath, of Vanderbilt University Medical Center, used self-reported assessments to measure compliance (rated 0% - 100%) among 37 children with EoE prior to their esophagogastroduodenoscopy (EGD).

The investigators also gathered demographic and clinical information, as well as PEC and EoE activity status. Active EoE was based on a PEC threshold of 15.

Thus, they found that the median self-reported compliance was 100% (range, 50-100%).

Furthermore, PEC was found to negatively correlate with increasing medication compliance (Spearmen’s rho = -0.33; P = .04).

Additionally, the median PEC was slightly lower in children with 100% compliance (3; range, 0-35) when compared with those with <100% compliance (40; range, 4-73).

And finally, Hiremath and colleagues reported that there was a significantly lower proportion of children with active EoE in the 100% compliance group (38%) than the lower compliance group (64%).

There was no noted association between demographic / clinical factors and 100% compliance to PPI / TS.

The team recognized that higher powered studies that use more objective methods to determine medication adherence are warranted.

Hiremath spoke with HCPLive® about these potential challenges that may prevent pediatric patients from strictly adhering to their medication, such an inability to swallow pills or fasting requirements.

He emphasized the importance of synergy between guardians and clinicians in helping to overcome these challenges.

“Especially in the world of EoE, there’s a lot of teamwork where the family and physicians work together,” he said. “So, I think it’ll be important for the physicians to have an ear for what kind of barriers the family or the patient faces and how [they] can help them overcome those barriers.”

Related Videos
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
Christine Frissora, MD | Credit: Weill Cornell
Hope on the Horizon: 2 Food Allergy Breakthroughs in 2024
Nathan D. Wong, MD, PhD: Growing Role of Lp(a) in Cardiovascular Risk Assessment | Image Credit: UC Irvine
Discussing FDA Approval of Tapinarof Cream for Atopic Dermatitis, with John Browning, MD
Laurence Sperling, MD: Expanding Cardiologists' Role in Obesity Management  | Image Credit: Emory University
Laurence Sperling, MD: Multidisciplinary Strategies to Combat Obesity Epidemic | Image Credit: Emory University
© 2024 MJH Life Sciences

All rights reserved.